Related Experiment Video
Updated: Dec 25, 2025
08:49
Cultivating a Three-dimensional Reconstructed Human Epidermis at a Large Scale
Published on: May 28, 2021
12.6K
A New Model Applied for Evaluating a Rhenium-diselenium Drug: Breast Cancer Cells Stimulated by Cytokines Induced
Vijay Veena1, Adhikesavan Harikrishnan2, Basavegowda Lakshmi3
1Biotechnology Department, REVA University, Bangalore, India btveenavijaykumar@gmail.com veena.v@reva.edu.in philippe.collery@gmail.com.
Anticancer Research
|April 3, 2020
Summary
A novel rhenium-diselenium (Re-diSe) anticancer drug showed efficacy in a new enriched medium model that better mimics the tumor microenvironment. This enriched medium, containing inflammatory cytokines, revealed drug sensitivity and reduced tumor growth factors.
Area of Science:
- Oncology
- Drug Discovery
- Cancer Biology
Background:
- Standard anticancer drug testing uses cell cultures in basic media.
- The tumor microenvironment contains inflammatory cytokines that influence drug efficacy.
- A new enriched medium (EM) was developed to better simulate the tumor microenvironment.
Purpose of the Study:
- To evaluate a rhenium-diselenium (Re-diSe) drug in a novel enriched medium (EM) model.
- To compare cytokine concentrations in EM versus control medium (CM).
- To assess the drug's effect on cancer cell growth and reactive oxygen species (ROS) production in the EM model.
Main Methods:
- Human breast cancer cells were cultured in CM or EM with or without Re-diSe.
- Cytokine levels (TNFα, IL6, IL1β, TGFβ, IGF1, VEGFA) were measured using ELISA.
- Cell growth and ROS production were quantified.
Main Results:
- EM showed significantly higher concentrations of TNFα, IL6, and IL1β compared to CM.
- Re-diSe treatment reduced TGFβ, IGF1, VEGFA, and ROS levels.
- The drug's half-maximal inhibitory concentration was higher in EM, indicating sensitivity within the simulated tumor microenvironment.
Conclusions:
- The enriched medium model effectively reflects aspects of the tumor microenvironment.
- The rhenium-diselenium (Re-diSe) drug demonstrated efficacy in this advanced cancer model.
- This model provides a more relevant platform for testing novel anticancer agents.
